{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T11:44:12Z","timestamp":1794397452784,"version":"4.9.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Portal vein tumor thrombus (PVTT) develops in up to half of patients with hepatocellular carcinoma (HCC) and historically signifies advanced-stage disease with limited treatment options and poor prognosis. Systemic therapy has been the standard treatment for HCC with PVTT, but this review highlights the potential of image-guided locoregional therapies including transarterial chemoembolization (TACE), transarterial embolization (TAE) radioembolization (TARE), hepatic arterial infusion chemotherapy (HAIC), and ablative or radiotherapeutic approaches to improve outcomes in this challenging context. We will summarize current evidence and clinical experience demonstrating that these modalities can achieve meaningful tumor control and extend survival, especially when tailored to tumor burden and PVTT extent or combined with systemic treatments. These findings underscore that aggressive locoregional treatment can be a valuable component of multidisciplinary management for advanced HCC, offering select patients an improved prognosis despite PVTT.<\/jats:p>","DOI":"10.1007\/s12029-025-01280-2","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T08:51:50Z","timestamp":1753260710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus"],"prefix":"10.1007","volume":"56","author":[{"given":"Ramanpreet","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina S.","family":"Makary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"1280_CR1","doi-asserted-by":"publisher","first-page":"28131","DOI":"10.1038\/s41598-024-77658-2","volume":"14","author":"Q Guo","year":"2024","unstructured":"Guo Q, Zhu X, Beeraka NM, Zhao R, Li S, Li F, Mahesh PA, Nikolenko VN, Fan R, Liu J. Projected epidemiological trends and burden of liver cancer by 2040 based on GBD, CI5plus, and WHO data. Sci Rep. 2024;14:28131. https:\/\/doi.org\/10.1038\/s41598-024-77658-2.","journal-title":"Sci Rep"},{"key":"1280_CR2","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.2147\/JHC.S474922","volume":"11","author":"Y Li","year":"2024","unstructured":"Li Y, Fan N, He X, Zhu J, Zhang J, Lu L. Research progress in predicting hepatocellular carcinoma with portal vein tumour thrombus in the era of artificial intelligence. J Hepatocell Carcinoma. 2024;11:1429\u201338. https:\/\/doi.org\/10.2147\/JHC.S474922.","journal-title":"J Hepatocell Carcinoma"},{"key":"1280_CR3","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.3390\/cancers16071271","volume":"16","author":"AM Jipa","year":"2024","unstructured":"Jipa AM, Makary MS. Locoregional Therapies for hepatobiliary tumors: contemporary strategies and novel applications. Cancers. 2024;16: 1271. https:\/\/doi.org\/10.3390\/cancers16071271.","journal-title":"Cancers"},{"key":"1280_CR4","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/biology12070999","volume":"12","author":"CR Criss","year":"2023","unstructured":"Criss CR, Makary MS. Recent advances in image-guided locoregional therapies for primary liver tumors. Biology. 2023;12: 999. https:\/\/doi.org\/10.3390\/biology12070999.","journal-title":"Biology"},{"key":"1280_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.4329\/wjr.v16.i10.512","volume":"16","author":"K Hao","year":"2024","unstructured":"Hao K, Paik AJ, Han LH, Makary MS. Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma. World J Radiol. 2024;16:512\u201327. https:\/\/doi.org\/10.4329\/wjr.v16.i10.512.","journal-title":"World J Radiol"},{"key":"1280_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1055\/s-0038-1666805","volume":"38","author":"P-H Liu","year":"2018","unstructured":"Liu P-H, Huo T-I, Miksad R. Hepatocellular carcinoma with portal vein tumor involvement: best management strategies. Semin Liver Dis. 2018;38:242\u201351. https:\/\/doi.org\/10.1055\/s-0038-1666805.","journal-title":"Semin Liver Dis"},{"key":"1280_CR7","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.3390\/cancers13215430","volume":"13","author":"KE Zane","year":"2021","unstructured":"Zane KE, Makary MS. Locoregional therapies for hepatocellular carcinoma with portal vein tumor thrombosis. Cancers. 2021;13: 5430. https:\/\/doi.org\/10.3390\/cancers13215430.","journal-title":"Cancers"},{"key":"1280_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2147\/JHC.S291530","volume":"8","author":"N Nevarez","year":"2021","unstructured":"Nevarez N, Yopp A. Challenging the treatment paradigm: selecting patients for surgical management of hepatocellular carcinoma with portal vein tumor thrombus. J Hepatocell Carcinoma. 2021;8:851\u201360. https:\/\/doi.org\/10.2147\/JHC.S291530.","journal-title":"J Hepatocell Carcinoma"},{"key":"1280_CR9","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1200\/JCO.2023.41.4_suppl.552","volume":"41","author":"S Vikash","year":"2023","unstructured":"Vikash S, Bteich F, Jiang J, Kanmaniraja D, Acuna-Villaorduna A, Saenger YM, Goel S, Kaubisch A. Malignant portal vein tumor thrombosis (PVTT) in patients with hepatocellular (HCC) carcinoma: Insights from a Western single-institutional cohort. J Clin Oncol. 2023;41:552\u2013552. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.552.","journal-title":"J Clin Oncol"},{"key":"1280_CR10","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1007\/s10620-016-4319-7","volume":"61","author":"G Garcia-Tsao","year":"2016","unstructured":"Garcia-Tsao G. The Child-Turcotte classification: from gestalt to sophisticated statistics and back. Dig Dis Sci. 2016;61:3102\u20134. https:\/\/doi.org\/10.1007\/s10620-016-4319-7.","journal-title":"Dig Dis Sci"},{"key":"1280_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","volume":"19","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Br\u00fa C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329\u201338. https:\/\/doi.org\/10.1055\/s-2007-1007122.","journal-title":"Semin Liver Dis"},{"key":"1280_CR12","doi-asserted-by":"publisher","unstructured":"Cheng S, Yang J, Shen F, Zhou W, Wang Y, Cong W, Yang GS, Cheng H, Hu H, Gao C, Guo J, Li A, Meng Y, Jiang X, Yang Y, Qian G, Luo M, Hu B, Man X, Zhang B, Su C, Zhou F, Li N, Shi J, Wang M, Zheng Y, Guo W, Sun J, Wang H, Lau W-Y, Wu M-C. Multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus - Eastern Hepatobiliary Surgical Hospital consensus statement. Oncotarget. 2016;7:40816\u201340829. https:\/\/doi.org\/10.18632\/oncotarget.8386.","DOI":"10.18632\/oncotarget.8386"},{"key":"1280_CR13","first-page":"S14","volume":"5","author":"BJ May","year":"2012","unstructured":"May BJ, Murthy R, Madoff DC. What\u2019s new in transarterial therapies for hepatocellular carcinoma? Gastrointest Cancer Res GCR. 2012;5:S14\u201319.","journal-title":"Gastrointest Cancer Res GCR"},{"key":"1280_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12876-024-03282-z","volume":"24","author":"G Wang","year":"2024","unstructured":"Wang G, Zhang J, Liu H, Zheng Q, Sun P. Embolization alone is as effective as TACE for unresectable HCC: systematic review and meta-analysis of randomized controlled trails. BMC Gastroenterol. 2024;24:195. https:\/\/doi.org\/10.1186\/s12876-024-03282-z.","journal-title":"BMC Gastroenterol"},{"key":"1280_CR15","doi-asserted-by":"crossref","unstructured":"Sutphin PD, Lamus D, Kalva SP, Li J, Corbin IR. Interventional radiologic therapies for hepatocellular carcinoma: from where we began to where we are going. In: Hoshida Y, (ed). Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. p. 169\u201394.","DOI":"10.1007\/978-3-030-21540-8_9"},{"key":"1280_CR16","doi-asserted-by":"publisher","first-page":"7462","DOI":"10.3748\/wjg.v27.i43.7462","volume":"27","author":"MS Makary","year":"2021","unstructured":"Makary MS, Ramsell S, Miller E, Beal EW, Dowell JD. Hepatocellular carcinoma locoregional therapies: outcomes and future horizons. World J Gastroenterol. 2021;27:7462\u201379. https:\/\/doi.org\/10.3748\/wjg.v27.i43.7462.","journal-title":"World J Gastroenterol"},{"key":"1280_CR17","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.3748\/wjg.v21.i12.3462","volume":"21","author":"M Quirk","year":"2015","unstructured":"Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol. 2015;21:3462\u201371. https:\/\/doi.org\/10.3748\/wjg.v21.i12.3462.","journal-title":"World J Gastroenterol"},{"key":"1280_CR18","doi-asserted-by":"publisher","unstructured":"El Hassani Y, Janati Idrissi K, Haloua M, Alami B, Hafidi Y, Boubbou M, Maaroufi M, Alaoui Lamrani Moulay Y. Liver abscess and portal vein thrombosis complicating TACE for HCC: case study and literature review. J Clin Gastroenterol Treat. 2020;6. https:\/\/doi.org\/10.23937\/2469-584X\/1510076.","DOI":"10.23937\/2469-584X\/1510076"},{"key":"1280_CR19","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"C-M Lo","year":"2002","unstructured":"Lo C-M, Ngan H, Tso W-K, Liu C-L, Lam C-M, Poon RT-P, Fan S-T, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatol Baltim Md. 2002;35:1164\u201371. https:\/\/doi.org\/10.1053\/jhep.2002.33156.","journal-title":"Hepatol Baltim Md"},{"key":"1280_CR20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3350\/cmh.2023.0202","volume":"29","author":"Cho Y, Choi JW, Kwon H, Kim KY, Lee BC, Chu HH, Lee DH, Lee HA, Kim GM, Oh JS, Hyun D, Lee IJ, Rhim H, Research Committee of the Korean Liver Cancer Association","year":"2023","unstructured":"Cho Y, Choi JW, Kwon H, Kim KY, Lee BC, Chu HH, Lee DH, Lee HA, Kim GM, Oh JS, Hyun D, Lee IJ, Rhim H, Research Committee of the Korean Liver Cancer Association. Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association. Clin Mol Hepatol. 2023;29:521\u201341. https:\/\/doi.org\/10.3350\/cmh.2023.0202.","journal-title":"Clin Mol Hepatol"},{"key":"1280_CR21","doi-asserted-by":"publisher","unstructured":"Zhong B-Y, Jin Z-C, Chen J-J, Zhu H-D, Zhu X-L (2022) Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Clin Transl Hepatol. 000:000\u2013000. https:\/\/doi.org\/10.14218\/JCTH.2022.00293.","DOI":"10.14218\/JCTH.2022.00293"},{"key":"1280_CR22","doi-asserted-by":"publisher","first-page":"e0309693","DOI":"10.1371\/journal.pone.0309693","volume":"19","author":"MS Makary","year":"2024","unstructured":"Makary MS, Alexander J, Regalado LE, Jalil S, Mumtaz K. Clinical outcomes of DEB-TACE in locally advanced hepatocellular carcinoma: a 5-year real world experience. PLoS ONE. 2024;19: e0309693. https:\/\/doi.org\/10.1371\/journal.pone.0309693.","journal-title":"PLoS ONE"},{"key":"1280_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40644-023-00581-8","volume":"23","author":"J Chen","year":"2023","unstructured":"Chen J, Lai L, Zhou C, Luo J, Wang H, Li M, Huang M. Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus. Cancer Imaging. 2023;23:70. https:\/\/doi.org\/10.1186\/s40644-023-00581-8.","journal-title":"Cancer Imaging"},{"key":"1280_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/JCO.22.00392","volume":"41","author":"Z Peng","year":"2023","unstructured":"Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, Huang F, Tang R, Cheng Y, Huang Z, Liang Y, Fan H, Qiao L, Li F, Zhuang W, Peng B, Wang J, Li J, Kuang M. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41:117\u201327. https:\/\/doi.org\/10.1200\/JCO.22.00392.","journal-title":"J Clin Oncol"},{"key":"1280_CR25","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.3390\/biomedicines12092124","volume":"12","author":"R You","year":"2024","unstructured":"You R, Cheng Y, Diao L, Wang C, Leng B, Yu Z, Xu Q, Yin G. Immune-targeted therapy with or without transarterial chemoembolization (TACE) for advanced hepatocellular carcinoma with portal vein tumor thrombosis (PVTT): a multicenter retrospective study. Biomedicines. 2024;12: 2124. https:\/\/doi.org\/10.3390\/biomedicines12092124.","journal-title":"Biomedicines"},{"key":"1280_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/jamasurg.2024.0506","volume":"159","author":"Z Peng","year":"2024","unstructured":"Peng Z, Fan W, Liu Z, Xiao H, Wu J, Tang R, Tu J, Qiao L, Huang F, Xie W, Zhuang W, Guo W, Li S, Hua Y, Shen S, He Q, Li D, Li J, Kuang M. Adjuvant transarterial chemoembolization with sorafenib for portal vein tumor thrombus: a randomized clinical trial. JAMA Surg. 2024;159:616\u201324. https:\/\/doi.org\/10.1001\/jamasurg.2024.0506.","journal-title":"JAMA Surg"},{"key":"1280_CR27","doi-asserted-by":"publisher","first-page":"1320818","DOI":"10.3389\/fonc.2023.1320818","volume":"13","author":"A Dong","year":"2023","unstructured":"Dong A, Zhu M, Zhang Z, Fan W, Wu Z, Chen Y, Tu J, Zhang Y, Zhuang W, He X, Peng Z. Efficacy of radiation plus transarterial chemoembolization and lenvatinib in hepatocellular carcinoma with portal vein tumor thrombus. Front Oncol. 2023;13: 1320818. https:\/\/doi.org\/10.3389\/fonc.2023.1320818.","journal-title":"Front Oncol"},{"key":"1280_CR28","doi-asserted-by":"publisher","first-page":"25616","DOI":"10.1038\/s41598-024-74801-x","volume":"14","author":"M Wang","year":"2024","unstructured":"Wang M, Cheng J, Qian N. Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization plus lenvatinib for intermediate hepatocellular carcinoma. Sci Rep. 2024;14:25616. https:\/\/doi.org\/10.1038\/s41598-024-74801-x.","journal-title":"Sci Rep"},{"key":"1280_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12876-021-02004-z","volume":"21","author":"K Bannangkoon","year":"2021","unstructured":"Bannangkoon K, Hongsakul K, Tubtawee T. Impact of cone-beam computed tomography with automated feeder detection software on the survival outcome of patients with hepatocellular carcinoma during treatment with conventional transarterial chemoembolization. BMC Gastroenterol. 2021;21:419. https:\/\/doi.org\/10.1186\/s12876-021-02004-z.","journal-title":"BMC Gastroenterol"},{"key":"1280_CR30","doi-asserted-by":"publisher","first-page":"923566","DOI":"10.3389\/fonc.2022.923566","volume":"12","author":"C He","year":"2022","unstructured":"He C, Ge N, Wang X, Li H, Chen S, Yang Y. Conversion therapy of large unresectable hepatocellular carcinoma with ipsilateral portal vein tumor thrombus using portal vein embolization plus transcatheter arterial chemoembolization. Front Oncol. 2022;12: 923566. https:\/\/doi.org\/10.3389\/fonc.2022.923566.","journal-title":"Front Oncol"},{"key":"1280_CR31","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.2147\/JHC.S428980","volume":"10","author":"S-Q Li","year":"2023","unstructured":"Li S-Q, Wu J-Y, Wu J-Y, Xie H, Li J-H, Zeng Z-X, Fu Y-K, Liu D-Y, Li H, Chen W-Z, Huang J-Y, Yan M-L. Transarterial chemoembolization plus Lenvatinib and PD-1 inhibitors for hepatocellular carcinoma with main trunk portal vein tumor thrombus: a multicenter retrospective study. J Hepatocell Carcinoma. 2023;10:1799\u2013811. https:\/\/doi.org\/10.2147\/JHC.S428980.","journal-title":"J Hepatocell Carcinoma"},{"key":"1280_CR32","doi-asserted-by":"publisher","first-page":"e34674","DOI":"10.1097\/MD.0000000000034674","volume":"102","author":"N \u015eener","year":"2023","unstructured":"\u015eener N, Yakupo\u011flu A. Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement. Medicine (Baltimore). 2023;102: e34674. https:\/\/doi.org\/10.1097\/MD.0000000000034674.","journal-title":"Medicine (Baltimore)"},{"key":"1280_CR33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12876-022-02204-1","volume":"22","author":"A Mahvash","year":"2022","unstructured":"Mahvash A, Chartier S, Turco M, Habib P, Griffith S, Brown S, Kappadath SC. A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study. BMC Gastroenterol. 2022;22:151. https:\/\/doi.org\/10.1186\/s12876-022-02204-1.","journal-title":"BMC Gastroenterol"},{"key":"1280_CR34","doi-asserted-by":"publisher","first-page":"100633","DOI":"10.1016\/j.jhepr.2022.100633","volume":"5","author":"F Kolligs","year":"2023","unstructured":"Kolligs F, Arnold D, Golfieri R, Pech M, Peynircioglu B, Pfammatter T, Ronot M, Sangro B, Schaefer N, Maleux G, Munneke G, Pereira H, Zeka B, de Jong N, Helmberger T, Principal Investigators CIRT. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: results from the prospective CIRT study. JHEP Rep Innov Hepatol. 2023;5: 100633. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100633.","journal-title":"JHEP Rep Innov Hepatol"},{"key":"1280_CR35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2967\/jnumed.123.266211","volume":"65","author":"E Garin","year":"2024","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Rolland Y, De Baere T, Assenat E, Tacher V, Palard X, D\u00e9andreis D, Mariano-Goulart D, Amaddeo G, Boudjema K, Hollebecque A, Meerun MA, Regnault H, Vibert E, Campillo-Gimenez B, Edeline J. Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial. J Nucl Med. 2024;65:264\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.266211.","journal-title":"J Nucl Med"},{"key":"1280_CR36","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3350\/cmh.2023.0076","volume":"29","author":"MH Hur","year":"2023","unstructured":"Hur MH, Cho Y, Kim DY, Lee JS, Kim GM, Kim H-C, Sinn DH, Hyun D, Lee HA, Seo YS, Lee IJ, Park J-W, Kim YJ. Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol. 2023;29:763\u201378. https:\/\/doi.org\/10.3350\/cmh.2023.0076.","journal-title":"Clin Mol Hepatol"},{"key":"1280_CR37","doi-asserted-by":"publisher","first-page":"101342","DOI":"10.1016\/j.jceh.2023.101342","volume":"14","author":"A Baloji","year":"2024","unstructured":"Baloji A, Kalra N, Chaluvashetty S, Bhujade H, Chandel K, Duseja A, Taneja S, Gorsi U, Kumar R, Singh H, Sood A, Bhattacharya A, Singh B, Mittal BR, Singh V, Sandhu MS. Efficacy of Yttrium-90 transarterial radioembolisation in advanced hepatocellular carcinoma: an experience with hybrid angio-computed tomography and glass microspheres. J Clin Exp Hepatol. 2024;14: 101342. https:\/\/doi.org\/10.1016\/j.jceh.2023.101342.","journal-title":"J Clin Exp Hepatol"},{"key":"1280_CR38","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/oncolo\/oyad331","volume":"29","author":"S Yu","year":"2024","unstructured":"Yu S, Yu M, Keane B, Mauro DM, Helft PR, Harris WP, Sanoff HK, Johnson MS, O\u2019Neil B, McRee AJ, Somasundaram A. A pilot study of pembrolizumab in combination with Y90 radioembolization in subjects with poor prognosis hepatocellular carcinoma. Oncologist. 2024;29:270\u2013e413. https:\/\/doi.org\/10.1093\/oncolo\/oyad331.","journal-title":"Oncologist"},{"key":"1280_CR39","doi-asserted-by":"publisher","unstructured":"Goswami P, Adeniran OR, K Frantz S, Matsuoka L, Du L, Gandhi RT, Collins ZS, Matrana MR, Petroziello M, Brower JS, Sze DY, Kennedy AS, Golzarian J, Wang EA, Brown DB. Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C). BMC Gastroenterol. 2022;22:467. https:\/\/doi.org\/10.1186\/s12876-022-02528-y.","DOI":"10.1186\/s12876-022-02528-y"},{"key":"1280_CR40","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1007\/s12072-024-10672-8","volume":"18","author":"Y Li","year":"2024","unstructured":"Li Y, Guo J, Liu W, Pang H, Song Y, Wu S, Zhang F, Yan D, Chen J, An C, Li C. Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis. Hepatol Int. 2024;18:1286\u201398. https:\/\/doi.org\/10.1007\/s12072-024-10672-8.","journal-title":"Hepatol Int"},{"key":"1280_CR41","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.3390\/cancers14194873","volume":"14","author":"Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Tani J, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Tanaka S, Deguchi A, Shimose S, Shirono T, Sakai M, Suzuki H, Moriyama E, Koga H, Torimura T, Kawaguchi T, New Fp Study Group null, Kurume Liver Cancer Study Group Of Japan null","year":"2022","unstructured":"Iwamoto H, Niizeki T, Nagamatsu H, Ueshima K, Tani J, Kuzuya T, Kasai K, Kooka Y, Hiraoka A, Sugimoto R, Yonezawa T, Tanaka S, Deguchi A, Shimose S, Shirono T, Sakai M, Suzuki H, Moriyama E, Koga H, Torimura T, Kawaguchi T, New Fp Study Group null, Kurume Liver Cancer Study Group Of Japan null. The clinical impact of hepatic arterial infusion chemotherapy new-FP for hepatocellular carcinoma with preserved liver function. Cancers. 2022;14: 4873. https:\/\/doi.org\/10.3390\/cancers14194873.","journal-title":"Cancers"},{"key":"1280_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00280-018-3638-0","volume":"82","author":"JH Choi","year":"2018","unstructured":"Choi JH, Chung WJ, Bae SH, Song DS, Song MJ, Kim YS, Yim HJ, Jung YK, Suh SJ, Park JY, Kim DY, Kim SU, Cho SB. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2018;82:469\u201378. https:\/\/doi.org\/10.1007\/s00280-018-3638-0.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1280_CR43","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.21.00608","volume":"40","author":"Q-J Li","year":"2022","unstructured":"Li Q-J, He M-K, Chen H-W, Fang W-Q, Zhou Y-M, Xu L, Wei W, Zhang Y-J, Guo Y, Guo R-P, Chen M-S, Shi M. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40:150\u201360. https:\/\/doi.org\/10.1200\/JCO.21.00608.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1280_CR44","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1148\/radiol.211545","volume":"303","author":"K Zheng","year":"2022","unstructured":"Zheng K, Zhu X, Fu S, Cao G, Li W-Q, Xu L, Chen H, Wu D, Yang R, Wang K, Liu W, Wang H, Bao Q, Liu M, Hao C, Shen L, Xing B, Wang X. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial. Radiology. 2022;303:455\u201364. https:\/\/doi.org\/10.1148\/radiol.211545.","journal-title":"Radiology"},{"key":"1280_CR45","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2147\/JHC.S456460","volume":"11","author":"G Liu","year":"2024","unstructured":"Liu G, Zhu D, He Q, Zhou C, He L, Li Z, Jiang Z, Huang M, Chang B, Wu C. Hepatic Arterial Infusion hemotherapy combined with lenvatinib and PD-1 inhibitors for managing arterioportal shunt in hepatocellular carcinoma with portal vein tumor thrombus: a retrospective cohort study. J Hepatocell Carcinoma. 2024;11:1415\u201328. https:\/\/doi.org\/10.2147\/JHC.S456460.","journal-title":"J Hepatocell Carcinoma"},{"key":"1280_CR46","doi-asserted-by":"publisher","first-page":"e7105","DOI":"10.1002\/cam4.7105","volume":"13","author":"S Fu","year":"2024","unstructured":"Fu S, Xu Y, Mao Y, He M, Chen Z, Huang S, Li D, Lv Y, Wu J. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: a promising treatment approach for high-burden hepatocellular carcinoma. Cancer Med. 2024;13: e7105. https:\/\/doi.org\/10.1002\/cam4.7105.","journal-title":"Cancer Med"},{"key":"1280_CR47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12072-024-10762-7","volume":"19","author":"S Tang","year":"2025","unstructured":"Tang S, Shi F, Xiao Y, Cai H, Ma P, Zhou Y, Wu Z, Chen S, Guo W. HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion. Hepatol Int. 2025;19:106\u201317. https:\/\/doi.org\/10.1007\/s12072-024-10762-7.","journal-title":"Hepatol Int"},{"key":"1280_CR48","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.3390\/jcm13072128","volume":"13","author":"M Mizandari","year":"2024","unstructured":"Mizandari M, Gotsiridze E, Keshavarz P, Nezami N, Azrumelashvili T, Nejati SF, Habib N, Chiang J, Raman SS. Endoportal radiofrequency ablation and stent placement in patients with portal vein tumor thrombosis from hepatocellular carcinoma: a study on feasibility and safety. J Clin Med. 2024;13: 2128. https:\/\/doi.org\/10.3390\/jcm13072128.","journal-title":"J Clin Med"},{"key":"1280_CR49","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00464-022-09639-3","volume":"37","author":"Y-L Kong","year":"2023","unstructured":"Kong Y-L, Sun J-J, Zhang H-Y, Xing Y, Wang C, Liu Y, He X-J, Kong L-H, Liu C-L. Clinical evaluation of percutaneous endovascular radiofrequency ablation for portal vein tumor thrombus: experience in 120 patients. Surg Endosc. 2023;37:1173\u201380. https:\/\/doi.org\/10.1007\/s00464-022-09639-3.","journal-title":"Surg Endosc"},{"key":"1280_CR50","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1007\/s00330-020-07571-5","volume":"31","author":"C An","year":"2021","unstructured":"An C, Li W-Z, Huang Z-M, Yu X-L, Han Y-Z, Liu F-Y, Wu S-S, Yu J, Liang P, Huang J. Small single perivascular hepatocellular carcinoma: comparisons of radiofrequency ablation and microwave ablation by using propensity score analysis. Eur Radiol. 2021;31:4764\u201373. https:\/\/doi.org\/10.1007\/s00330-020-07571-5.","journal-title":"Eur Radiol"},{"key":"1280_CR51","doi-asserted-by":"publisher","first-page":"20200415","DOI":"10.1259\/bjr.20200415","volume":"94","author":"WP Zhao","year":"2021","unstructured":"Zhao WP, Li H, Guo J, Cai L, Duan Y, Hou X, Du H, Shao X, Diao Z, Li C. Hepatocellular carcinoma with type II-III portal vein tumour thrombosis: treatment using transarterial chemoembolisation and microwave ablation. Br J Radiol. 2021;94: 20200415. https:\/\/doi.org\/10.1259\/bjr.20200415.","journal-title":"Br J Radiol"},{"key":"1280_CR52","doi-asserted-by":"publisher","first-page":"1097625","DOI":"10.3389\/fimmu.2022.1097625","volume":"13","author":"Q Shi","year":"2023","unstructured":"Shi Q, Zhou X, Zhang Z, Zhang W, Ma J, Yang M, Yu J, Luo J, Liu L, Yan Z. Microwave ablation and synchronous transarterial chemoembolization combined with PD-1 inhibitor in patients with hepatocellular carcinoma following tyrosine kinase inhibitor intolerance. Front Immunol. 2023;13: 1097625. https:\/\/doi.org\/10.3389\/fimmu.2022.1097625.","journal-title":"Front Immunol"},{"key":"1280_CR53","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/02656736.2021.2021303","volume":"39","author":"Q Zhou","year":"2022","unstructured":"Zhou Q, An Y, Liu T, Liu Z, Li R, Wang C, Zhou F, Liu C, Zhu K. Prognosis of patients with hepatocellular carcinoma and portal vein tumor thrombus treated with combination of transarterial chemoembolization and palliative thermal ablation. Int J Hyperthermia. 2022;39:97\u2013107. https:\/\/doi.org\/10.1080\/02656736.2021.2021303.","journal-title":"Int J Hyperthermia"},{"key":"1280_CR54","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.2147\/JHC.S426308","volume":"10","author":"Q Shi","year":"2023","unstructured":"Shi Q, Huang P, Zhang Z, Zhang W, Liu L, Yan Z. Hepatocellular carcinoma with radiological progression: lenvatinib plus PD-1 inhibitor combined with microwave ablation and synchronous transarterial chemoembolization. J Hepatocell Carcinoma. 2023;10:1861\u201371. https:\/\/doi.org\/10.2147\/JHC.S426308.","journal-title":"J Hepatocell Carcinoma"},{"key":"1280_CR55","doi-asserted-by":"publisher","first-page":"1418965","DOI":"10.3389\/fimmu.2024.1418965","volume":"15","author":"L Hao","year":"2024","unstructured":"Hao L, Li S, Ye F, Wang H, Zhong Y, Zhang X, Hu X, Huang X. The current status and future of targeted-immune combination for hepatocellular carcinoma. Front Immunol. 2024;15: 1418965. https:\/\/doi.org\/10.3389\/fimmu.2024.1418965.","journal-title":"Front Immunol"},{"key":"1280_CR56","doi-asserted-by":"publisher","unstructured":"Yoon JH, Choi SK. Management of early-stage hepatocellular carcinoma: challenges and strategies for optimal outcomes. J Liver Cancer. 2023;23:300\u2013315. https:\/\/doi.org\/10.17998\/jlc.2023.08.27.","DOI":"10.17998\/jlc.2023.08.27"},{"key":"1280_CR57","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/liv.15169","volume":"42","author":"J Luo","year":"2022","unstructured":"Luo J, Dong Z, Xie H, Zhang W, An L, Yu Z, Chang X, Chen Y, Yang W, Hu K, Liu F, Yang Y. Efficacy and safety of percutaneous cryoablation for elderly patients with small hepatocellular carcinoma: a prospective multicenter study. Liver Int Off J Int Assoc Study Liver. 2022;42:918\u201329. https:\/\/doi.org\/10.1111\/liv.15169.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"1280_CR58","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.12845","author":"P Esposito","year":"2021","unstructured":"Esposito P, Matteo M, Concepcion C, Montanarella M, Matteo J. Portal vein tumor thrombus: no longer a death sentence. Cureus. 2021. https:\/\/doi.org\/10.7759\/cureus.12845.","journal-title":"Cureus"},{"key":"1280_CR59","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.3390\/cancers15123164","volume":"15","author":"J Kim","year":"2023","unstructured":"Kim J, Cheng JC-H, Nam T-K, Kim JH, Jang BK, Huang W-Y, Aikata H, Kim M, Kwon JH, Yue J, Lee VHF, Zeng Z, Seong J. Efficacy of liver-directed combined radiotherapy in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancers. 2023;15: 3164. https:\/\/doi.org\/10.3390\/cancers15123164.","journal-title":"Cancers"},{"key":"1280_CR60","doi-asserted-by":"publisher","first-page":"tzaf002","DOI":"10.1093\/bjro\/tzaf002","volume":"7","author":"P Sahai","year":"2025","unstructured":"Sahai P, Yadav HP, Choudhury A, Shasthry SM, Jindal A, Mall A, Mukund A, Patidar Y, Bharadwaj MS, Khangembam BC, Kumar G, Rastogi A, Pamecha V. Outcomes with radiotherapy in multimodality treatment for hepatocellular carcinoma with portal vein tumour thrombosis. BJR Open. 2025;7: tzaf002. https:\/\/doi.org\/10.1093\/bjro\/tzaf002.","journal-title":"BJR Open"},{"key":"1280_CR61","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1186\/s12885-025-13739-3","volume":"25","author":"SM Lee","year":"2025","unstructured":"Lee SM, Choi JH, Yoon J-H, Kim YJ, Yu SJ, Lee J-H, Kang H-C, Chie EK, Kim KS. Efficacy and safety of image-guided hypofractionated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective, multicenter study. BMC Cancer. 2025;25:736. https:\/\/doi.org\/10.1186\/s12885-025-13739-3.","journal-title":"BMC Cancer"},{"key":"1280_CR62","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.3390\/cancers16112050","volume":"16","author":"T Ishida","year":"2024","unstructured":"Ishida T, Mizumoto M, Saito T, Okumura T, Miura K, Makishima H, Iizumi T, Numajiri H, Baba K, Murakami M, Nakamura M, Nakai K, Sakurai H. Proton beam therapy for treating patients with hepatocellular carcinoma with major portal vein tumor invasion: a single center retrospective study. Cancers. 2024;16: 2050. https:\/\/doi.org\/10.3390\/cancers16112050.","journal-title":"Cancers"},{"key":"1280_CR63","doi-asserted-by":"publisher","first-page":"1458819","DOI":"10.3389\/fphar.2024.1458819","volume":"15","author":"M Zhang","year":"2024","unstructured":"Zhang M, Zheng Z, Ding Q, Su J, Xin Y, Jiang X. Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study. Front Pharmacol. 2024;15: 1458819. https:\/\/doi.org\/10.3389\/fphar.2024.1458819.","journal-title":"Front Pharmacol"},{"key":"1280_CR64","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13014-023-02270-z","volume":"18","author":"X Ji","year":"2023","unstructured":"Ji X, Xu Z, Sun J, Li W, Duan X, Wang Q. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study. Radiat Oncol. 2023;18:101. https:\/\/doi.org\/10.1186\/s13014-023-02270-z.","journal-title":"Radiat Oncol"},{"key":"1280_CR65","doi-asserted-by":"publisher","first-page":"101287","DOI":"10.1016\/j.jhepr.2024.101287","volume":"7","author":"Y Zhai","year":"2025","unstructured":"Zhai Y, Wang L, Zhao H, Wu F, Xin L, Ye F, Sun W, Song Y, Niu L, Zeng H, Wang J, Tang Y, Song Y, Liu Y, Fang H, Lu N, Jing H, Qi S, Zhang W, Wang S, Li Y-X, Wu J, Chen B. Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and\/or hepatic vein tumor thrombosis. JHEP Rep Innov Hepatol. 2025;7: 101287. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101287.","journal-title":"JHEP Rep Innov Hepatol"},{"key":"1280_CR66","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12893-024-02334-1","volume":"24","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Li K, Zhao Y, Yang S, Yan J, Xiang C, Zeng J, Lu Q, Zhang C, Li G, Li G, Dong J. Efficacy of radiotherapy in combined treatment of hepatocellular carcinoma patients with portal vein tumor thrombus: a real-world study. BMC Surg. 2024;24:54. https:\/\/doi.org\/10.1186\/s12893-024-02334-1.","journal-title":"BMC Surg"},{"key":"1280_CR67","doi-asserted-by":"publisher","first-page":"11315","DOI":"10.1002\/cam4.5841","volume":"12","author":"X Zou","year":"2023","unstructured":"Zou X, Xu Q, You R, Yin G. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features. Cancer Med. 2023;12:11315\u201333. https:\/\/doi.org\/10.1002\/cam4.5841.","journal-title":"Cancer Med"},{"key":"1280_CR68","doi-asserted-by":"publisher","first-page":"e222891","DOI":"10.1148\/radiol.222891","volume":"309","author":"C Hsieh","year":"2023","unstructured":"Hsieh C, Laguna A, Ikeda I, Maxwell AWP, Chapiro J, Nadolski G, Jiao Z, Bai HX. Using machine learning to predict response to image-guided therapies for hepatocellular carcinoma. Radiology. 2023;309: e222891. https:\/\/doi.org\/10.1148\/radiol.222891.","journal-title":"Radiology"},{"key":"1280_CR69","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1097\/JS9.0000000000001691","volume":"110","author":"T-Y Zhou","year":"2024","unstructured":"Zhou T-Y, Tao G-F, Zhou G-H, Zhang Y-L, Zhu T-Y, Chen S-Q, Wang H-L, Wang B-Q, Jing L, Chen F. Comparison of drug-eluting bead with conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a randomized clinical trial. Int J Surg Lond Engl. 2024;110:5527\u201337. https:\/\/doi.org\/10.1097\/JS9.0000000000001691.","journal-title":"Int J Surg Lond Engl"},{"key":"1280_CR70","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3390\/jcm14020314","volume":"14","author":"C Lanza","year":"2025","unstructured":"Lanza C, Ascenti V, Amato GV, Pellegrino G, Triggiani S, Tintori J, Intrieri C, Angileri SA, Biondetti P, Carriero S, Torcia P, Ierardi AM, Carrafiello G. All you need to know about TACE: a comprehensive review of indications, techniques, efficacy, limits, and technical advancement. J Clin Med. 2025;14: 314. https:\/\/doi.org\/10.3390\/jcm14020314.","journal-title":"J Clin Med"},{"key":"1280_CR71","doi-asserted-by":"publisher","first-page":"918","DOI":"10.3390\/jcm12030918","volume":"12","author":"MM Welling","year":"2023","unstructured":"Welling MM, Duszenko N, van Meerbeek MP, Molenaar TJM, Buckle T, van Leeuwen FWB, Rietbergen DDD. Microspheres as a carrier system for therapeutic embolization procedures: achievements and advances. J Clin Med. 2023;12: 918. https:\/\/doi.org\/10.3390\/jcm12030918.","journal-title":"J Clin Med"},{"key":"1280_CR72","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/jpm14070747","volume":"14","author":"C K\u00fchnel","year":"2024","unstructured":"K\u00fchnel C, K\u00f6hler A, Brachwitz T, Seifert P, G\u00fchne F, Aschenbach R, Freudenberg R, Freesmeyer M, Drescher R. Clinical results of Holmium-166 radioembolization with personalized dosimetry for the treatment of hepatocellular carcinoma. J Pers Med. 2024;14: 747. https:\/\/doi.org\/10.3390\/jpm14070747.","journal-title":"J Pers Med"},{"key":"1280_CR73","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3350\/cmh.2024.0516","volume":"30","author":"JH Kim","year":"2024","unstructured":"Kim JH, Kim GH, Gwon DI. Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: editorial on \u201ctransarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis.\u201d Clin Mol Hepatol. 2024;30:659\u201362. https:\/\/doi.org\/10.3350\/cmh.2024.0516.","journal-title":"Clin Mol Hepatol"},{"key":"1280_CR74","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","volume":"109","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, He W, Yang Z, Qiu J, Huang Z, Shi Y, Lin Z, Zheng Y, Chen M, Lau WY, Li B, Yuan Y. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int J Surg. 2023;109:1222\u201330. https:\/\/doi.org\/10.1097\/JS9.0000000000000256.","journal-title":"Int J Surg"},{"key":"1280_CR75","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.7150\/thno.68456","volume":"12","author":"P He","year":"2022","unstructured":"He P, Ren E, Chen B, Chen H, Cheng H, Gao X, Liang X, Liu H, Li J, Li B, Chen A, Chu C, Chen X, Mao J, Zhang Y, Liu G. A super-stable homogeneous Lipiodol-hydrophilic chemodrug formulation for treatment of hepatocellular carcinoma. Theranostics. 2022;12:1769\u201382. https:\/\/doi.org\/10.7150\/thno.68456.","journal-title":"Theranostics"},{"key":"1280_CR76","doi-asserted-by":"publisher","first-page":"104730","DOI":"10.1016\/j.critrevonc.2025.104730","volume":"211","author":"Q Wu","year":"2025","unstructured":"Wu Q, Zhao X, Yang C, Yuan Y, Yang H, Fu Q. Efficacy and safety of radiotherapy combined with immune checkpoint inhibitors for advanced or unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2025;211: 104730. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104730.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1280_CR77","doi-asserted-by":"publisher","first-page":"945123","DOI":"10.3389\/fonc.2022.945123","volume":"12","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhang X, Ding X, Wang Z, Fan Y, Chen G, Hu X, Zheng J, Xue Z, He X, Zhang X, Wei Y, Zhang Z, Li J, Li J, Yang J, Xue X, Ma L, Xiao Y. Novel irreversible electroporation ablation (Nano-knife) versus radiofrequency ablation for the treatment of solid liver tumors: a comparative, randomized, multicenter clinical study. Front Oncol. 2022;12: 945123. https:\/\/doi.org\/10.3389\/fonc.2022.945123.","journal-title":"Front Oncol"},{"key":"1280_CR78","first-page":"121","volume":"22","author":"O Kutsenko","year":"2023","unstructured":"Kutsenko O, Narayanan G, Gentile N, Gandhi R. Robotics in interventional oncology: the next frontier in image-guided interventions. Endovasc Today. 2023;22:121.","journal-title":"Endovasc Today"},{"key":"1280_CR79","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40164-025-00658-z","volume":"14","author":"X Yu","year":"2025","unstructured":"Yu X, Zhang Q, Wang L, Zhang Y, Zhu L. Engineered nanoparticles for imaging and targeted drug delivery in hepatocellular carcinoma. Exp Hematol Oncol. 2025;14:62. https:\/\/doi.org\/10.1186\/s40164-025-00658-z.","journal-title":"Exp Hematol Oncol"},{"key":"1280_CR80","doi-asserted-by":"publisher","first-page":"100873","DOI":"10.1016\/j.mtbio.2023.100873","volume":"23","author":"Q Shi","year":"2023","unstructured":"Shi Q, Zhang X, Wu M, Xia Y, Pan Y, Weng J, Li N, Zan X, Xia J. Emulsifying Lipiodol with pH-sensitive DOX@HmA nanoparticles for hepatocellular carcinoma TACE treatment eliminate metastasis. Mater Today Bio. 2023;23: 100873. https:\/\/doi.org\/10.1016\/j.mtbio.2023.100873.","journal-title":"Mater Today Bio"},{"key":"1280_CR81","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.2147\/IJN.S390384","volume":"18","author":"HJ Vaughan","year":"2023","unstructured":"Vaughan HJ, Zamboni CG, Luly KM, Li L, Gabrielson KL, Hassan LF, Radant NP, Bhardwaj P, Selaru FM, Pomper MG, Green JJ. Non-viral gene delivery to hepatocellular carcinoma via intra-arterial injection. Int J Nanomed. 2023;18:2525\u201337. https:\/\/doi.org\/10.2147\/IJN.S390384.","journal-title":"Int J Nanomed"},{"key":"1280_CR82","doi-asserted-by":"publisher","unstructured":"Peng Y, Liu H, Miao M, Cheng X, Chen S, Yan K, Mu J, Cheng H, Liu G. Micro-nano convergence-driven radiotheranostic revolution in hepatocellular carcinoma. ACS Appl Mater Interfaces acsami. 2025;5c05525. https:\/\/doi.org\/10.1021\/acsami.5c05525.","DOI":"10.1021\/acsami.5c05525"},{"key":"1280_CR83","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.3390\/cancers16233933","volume":"16","author":"G Wu","year":"2024","unstructured":"Wu G, Bajestani N, Pracha N, Chen C, Makary MS. Hepatocellular carcinoma surveillance strategies: major guidelines and screening advances. Cancers. 2024;16: 3933. https:\/\/doi.org\/10.3390\/cancers16233933.","journal-title":"Cancers"},{"key":"1280_CR84","doi-asserted-by":"publisher","unstructured":"Cheng S, Chen M, Cai J, Sun J, Guo R, Bi X, Lau WY, Wu M. Chinese Association of Liver Cancer and Chinese Medical Doctor Association (2020) Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 Edition). Liver Cancer. 2019;9:28\u201340. https:\/\/doi.org\/10.1159\/000503685.","DOI":"10.1159\/000503685"},{"key":"1280_CR85","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.3390\/cancers15133347","volume":"15","author":"A Podlasek","year":"2023","unstructured":"Podlasek A, Abdulla M, Broering D, Bzeizi K. Recent advances in locoregional therapy of hepatocellular carcinoma. Cancers. 2023;15: 3347. https:\/\/doi.org\/10.3390\/cancers15133347.","journal-title":"Cancers"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01280-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01280-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01280-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T08:51:53Z","timestamp":1753260713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01280-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1280"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01280-2","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"7 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review did not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"162"}}